

1 Todd M. Schneider (SBN 158253)

Jason H. Kim (SBN 220279)

2 Matthew S. Weiler (SBN 236052)

SCHNEIDER WALLACE

3 **COTTRELL KONECKY LLP**

4 2000 Powell Street, Suite 1400

Emeryville, CA 94608

5 Telephone: (415) 421-7100

TSchneider@schneiderwallace.com

6 JKim@schneiderwallace.com

MWeiler@schneiderwallace.com

7
8 Peter D. St. Phillip (*Pro hac vice* to be filed)

LOWEY DANNENBERG, P.C.

9 44 South Broadway, Suite 1100

White Plains, NY 10601

10 Telephone: (914) 997-0500

PStPhillip@lowey.com

11
12 [Additional counsel on signature page]

13
14 **UNITED STATES DISTRICT COURT**
15 **FOR THE NORTHERN DISTRICT OF CALIFORNIA**

16 MOLINA HEALTHCARE INC.,

17 Plaintiff,

18 vs.

19 JAZZ PHARMACEUTICALS, INC.;
JAZZ PHARMACEUTICALS IRELAND
LIMITED;
20 JAZZ PHARMACEUTICALS PUBLIC
LIMITED COMPANY;
21 HIKMA PHARMACEUTICALS PLC;
HIKMA PHARMACEUTICALS USA INC.;
22 HIKMA LABS, INC.;
EUROHEALTH (USA), INC.;
23 AMNEAL PHARMACEUTICALS LLC;
PAR PHARMACEUTICAL, INC.;
24 LUPIN LTD.;
LUPIN PHARMACEUTICALS INC.;
25 LUPIN INC.,

26 Defendants.

Case No.

COMPLAINT

JURY TRIAL DEMANDED

TABLE OF CONTENTS

1		
2	I. INTRODUCTION.....	1
3	II. JURISDICTION AND VENUE.....	4
4	III. THE PARTIES	4
5	IV. REGULATORY BACKGROUND	8
6	A. Regulatory Structure for Approval and Substitution of Generic Drugs.	8
7	1. The Prescription Drug Market Place	8
8	2. The Hatch-Waxman Act and FDA Approval Process.....	9
9	3. Use of Authorized Generics to Maximize Profits Following Generic Entry.	14
10	4. Acceleration Clauses As a “Poison Pill” to Further Generic Entry.	16
11	V. DEFENDANTS’ ANTICOMPETITIVE CONDUCT	17
12	A. The Development of Sodium Oxybate	17
13	B. Sodium Oxybate as a Treatment for Narcolepsy	18
14	C. Jazz Obtains All Rights To Xyrem Through Orphan Medical Acquisition	20
15	D. The Xyrem Patents	20
16	1. The ’431 Family Of Patents (Formulations And Methods Of Treatment)	21
17	2. The ’730 Family Of Patents (Drug Distribution System And Method)	22
18	3. The ’302 Family Of Patents (Method Of Administration)	22
19	E. Jazz Jacks Up Xyrem Prices “to the Moon”.....	23
20	F. Jazz Seeks A Multiple Pharmacy Rems In Conjunction With Its Request For Approval To	
21	Market Xyrem For Fibromyalgia.....	25
22	G. Generic Challengers Make Paragraph IV Certifications.....	25
23	H. Jazz Files Sham Litigation to Combat Roxane’s (Now Hikma’s) Threat.	26
24	I. Jazz Reverses Course In Its REMS Negotiations, Discouraging Generic Entry	27
25	K. The ’730 Family Are Declared Invalid in Inter Partes Review.	31
26	L. The Jazz-Hikma Reverse Payment Agreement.....	31
27	M. Jazz Enters Into Unlawful Reverse Payment Agreements With Par, Lupin, And Amneal: the	
28	Later Generic Defendants.....	34

1	N. The Jazz-Hikma Agreement Has Caused, And Will Continue To Cause, Anticompetitive Effects.....	36
2	VI. DEFENDANTS' ANTICOMPETITIVE EFFECTS IN THE MARKET FOR SODIUM	
3	OXYBATE.....	39
4	VII. JAZZ'S MONOPOLY POWER.....	40
5	VIII. EFFECTS ON TRADE AND COMMERCE.....	41
6	IX. ANTITRUST INJURY	41
7	X. PLAINTIFF'S CLAIMS ARE TIMELY.....	42
8	A. Defendants Fraudulently Concealed by Omission Their Unlawful Agreements.	42
9	B. Defendants' Continuing Violations.....	43
10	XI. CLAIMS FOR RELIEF	44
11	XII. DEMAND FOR JUDGMENT	62
12	XIII. JURY DEMAND	62

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

1. Plaintiff Molina Healthcare Inc. (“Molina” or “Plaintiff”) brings this action against Defendants Jazz Pharmaceuticals, Inc., Jazz Pharmaceuticals Ireland Limited, Jazz Pharmaceuticals Public Limited Company, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., Eurohealth (USA), Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals Inc., and Lupin Inc., (collectively, “Defendants”) for violations of antitrust, consumer protection, and common laws. Plaintiff’s claims concern Defendants’ scheme to restrain competition for branded Xyrem and its AB rated generic bioequivalents in the United States. Defendants, the brand manufacturer of Xyrem and several competitors, abused the patent laws for profit by allocating the market for a drug that was invented nearly 150 years ago. Sodium oxybate, sold under the brand name Xyrem (also known as γ -hydroxybutyric acid (GHB)) is a naturally occurring substance found in the central nervous system. Xyrem is manufactured by Jazz Pharmaceuticals, Inc and its affiliates (“Jazz”). Xyrem has historically been Jazz’s main source of revenue, making up 70% or more of its revenues since 2007. Jazz’s growth and profits have been entirely linked to its ability to increase prices on Xyrem and keep the market to itself. To prevent generic competition and unlawfully maintain this monopoly, Jazz first manipulated an FDA safety program meant to mitigate safety risks of certain drugs (“REMS”); engaged in sham patent litigation; abused the REMS process to further frustrate generic competitors; and finally agreed with other Defendants to delay generic entry in exchange for allocating the generic market for AB-rated generic Xyrem. All the while, Jazz imposed a series of grotesque price hikes that would have been impossible had generic entry been successful. This scheme caused Plaintiff to pay inflated prices for Xyrem from July 17, 2017 through the present, until the anticompetitive effects of the Defendants’ unlawful conduct cease.

I. INTRODUCTION

2. This litigation challenges a comprehensive anticompetitive scheme to suppress generic competition for Xyrem, a leading treatment of narcolepsy. Defendants abused an FDA drug safety program called “Risk Evaluation and Mitigation Strategy,” engaged in sham patent litigation, and entered into reverse payments to generic manufacturers to preserve their monopoly in Xyrem. Through this

1 scheme Defendants suppressed generic competition and raised the price of Xyrem 841% between 2007
2 and 2014. Third-party payors such as Plaintiff footed the bill for this manipulation.

3 3. Sodium oxybate, the active ingredient in Xyrem, is a central nervous system depressant
4 that has been widely available in the United States since the 1960s. Sodium oxybate is the chemically
5 derived version of γ -Hydroxybutyric acid (GHB), which occurs naturally in human bodies' central
6 nervous systems, as well as wine, beef, small citrus fruits, and almost all animals.¹

7 4. Narcolepsy is a disorder characterized by excessive daytime sleepiness ("EDS") and
8 intermittent manifestations of REM sleep during wakefulness. In 1994, the Food and Drug
9 Administration's ("FDA") Orphan Products Development Division and a non-profit advocacy
10 organization approached a small Minnesota-based drug company, Orphan Medical, to suggest the
11 development of sodium oxybate for treatment of cataplexy, which is a common symptom of narcolepsy
12 manifested by sudden episodes of bilateral skeletal muscle weakness induced by an emotional trigger
13 such as laughter, anger, embarrassment, or surprise.

14 5. Orphan Medical began development of what would become Xyrem and, in 2002,
15 obtained FDA approval to market sodium oxybate for the treatment of cataplexy associated with
16 narcolepsy in adults. Orphan branded its product Xyrem. In 2005, Orphan Medical obtained FDA
17 approval to market Xyrem for EDS associated with narcolepsy in adults. Until 2021, Xyrem was the
18 only drug approved by the FDA to treat both EDS and cataplexy associated with narcolepsy. In 2020,
19 the FDA also approved Jazz's follow-on sodium oxybate product, Xywav, for the treatment of those
20 conditions.

21 6. In 2005, Jazz Pharmaceuticals, Inc. acquired Orphan Medical. "The acquisition was
22 unprofitable at first By 2009, Jazz was on the verge of bankruptcy. ... Jazz responded by replacing
23 its management team."² Jazz then began a series of epic price hikes. In May of 2014, Bloomberg
24 published a ranking of drug price increases from 2007 to 2014. Xyrem ranked first with an overall
25

26 ¹ "Gamma-hydroxybutyric acid (GHB), Critical Review Report," World Health Organization Expert
Committee on Drug Dependence (2012);

27 https://www.who.int/medicines/areas/quality_safety/4.1GHBcritical_review.pdf

28 ² *In re Xyrem Antitrust Litig.*, Case No. 5:20-md-02966-LHK, ECF No. 138, at 2 (N.D. Cal. Aug. 13,
2021).



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.